Company intelligence / Profile preview

BioLeap

Ewing, New Jersey, United Statesbioleap.org ↗

Ownership: Private
Development stage: Preclinical

Overview

BioLeap (bioleap.ai) offers an advanced Hybrid-AI biosimulation engine that models complex biological systems to optimize immunotherapy development—including patient stratification, dosing strategies, combination therapy prediction—for pharma partners developing next-generation biologics/cell therapies. It does not have its own therapeutic pipeline.

Therapeutic areas: Oncology
Modalities: Small moleculesFragment-based design compoundsBiologicsCell therapiesCombination therapiesCAR-TCheckpoint inhibitors
Industry: Drug Discovery Services

Partnerships

For bioleap.ai: partnerships with forward-thinking cell therapy companies claimed but not named publicly yet.For BioLeap Inc: engaged in four collaborative ventures with undisclosed partners before closure.

Beyond the preview

Go deeper on BioLeap.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioLeap.

Explore the full profile